Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 9128 results

  1. GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]

    Awaiting development Reference number: GID-TA12009 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]

    Awaiting development Reference number: GID-TA12478 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]

    Awaiting development Reference number: GID-TA12469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Sacituzumab tirumotecan for treating endometrial cancer after platinum-based chemotherapy and immunotherapy

    Awaiting development Reference number: GID-TA12448 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Glofitamab for treating relapsed or refractory mantle cell lymphoma

    Awaiting development Reference number: GID-TA12447 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Garetosmab for preventing heterotopic ossification and flare ups associated with fibrodysplasia ossificans progressiva [ID3772]

    Awaiting development Reference number: GID-TA12522 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Urinary biomarker tests to detect bladder cancer

    Awaiting development Reference number: GID-HTG10903 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  11. Miniature lens system implantation for advanced age-related macular degeneration

    In development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    In development

  12. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

    NICE guideline
    Awaiting development

  13. Neurostimulation of lumbar multifidus for refractory chronic low back pain with lumbar multifidus dysfunction

    In development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    In development

  14. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5]

    Deferred Reference number: GID-TA10905

    Technology appraisal guidance
    Deferred

  15. Polyendocrine Metabolic Ovarian Syndrome (PMOS)

    In development Reference number: GID-NG10436 Expected publication date:  09 December 2026

    NICE guideline
    In development